Skip to main content
Clinical Trials/NL-OMON44139
NL-OMON44139
Recruiting
Not Applicable

TASMA Extension Study: Long Term Efficacy and Safety of Bronchial Thermoplasty in Severe Asthma. - TASMA extension study

Academisch Medisch Centrum0 sites35 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
asthma
Sponsor
Academisch Medisch Centrum
Enrollment
35
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • participation in the TASMA study

Exclusion Criteria

  • participating in another clinical trial involving respiratory intervention which in the opinion of the investigator might interfere with the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Unraveling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma (TASMA) Extension StudySevere Asthma
NCT02975284Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)30
Active, not recruiting
Not Applicable
Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)Rheumatoid Arthritis
NCT04862117SetPoint Medical Corporation14
Completed
Not Applicable
Efficacy trial and long-term safety confirmation test- Efficacy and long-term safety of the test food TK61406 ingested as a single dose, in a double-blind, parallel-group comparison to placebo.A range of individuals from healthy to borderline conditions- Persons with tendency for constipation or diarrhea- Persons classified as normal to 1 degree of obesity- Persons classified with normal to 1 degree of average blood pressure
JPRN-jRCT1091220210Tokai Pickling Co.,Ltd. Yasufumi Ohba, Masataka Fujita, Mitsuru Satsukawa, Tetsuhiro Kawamoto, Mika Komura, Shoko Nishio, Tetsuya Iyoda,Hiroshi Ono30
Active, not recruiting
Phase 1
The proposed study aims to build on the results of clinical studies DIUR-003 and DIUR-005 and evaluate the long-term safety of Chronocort® and also its long term efficacy.Congenital adrenal hyperplasia (CAH)is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, and androgen excess. Subjects with CAH are at risk of developing a number of clinical manifestations, such as obesity in children, insulin resistance, and polycystic ovaries, which may contribute to infertility in women with CAH. Oligomenorrhoea or amenorrhoea may be present in adolescence.MedDRA version: 20.0 Level: LLT Classification code 10010323 Term: Congenital adrenal hyperplasia System Organ Class: 100000004850Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2015-005448-32-SEDiurnal Ltd138
Active, not recruiting
Phase 1
The proposed study aims to build on the results of clinical studies DIUR-003 and DIUR-005 and evaluate the long-term safety of Chronocort® and also its long term efficacy.Congenital adrenal hyperplasia (CAH)is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, and androgen excess. Subjects with CAH are at risk of developing a number of clinical manifestations, such as obesity in children, insulin resistance, and polycystic ovaries, which may contribute to infertility in women with CAH. Oligomenorrhoea or amenorrhoea may be present in adolescence.MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2015-005448-32-DEDiurnal Ltd136